Management’s guidance upgrade for FY19
13/01/20 -"Given the strong uptake of Cimzia (33% of sales) and Vimpat (25% of sales) across geographies in Q4 19, we have upgraded our revenue estimates for the forecast years. Combined with robust operational ..."
Pages
51
Language
English
Published on
13/01/20
You may also be interested by these reports :
12/08/26
With the Astra-BMS merger idea likely being shelved after apprehensions raised by various analysts/investors, we re-float the idea of an Astra-GSK ...
10/08/26
The Q2 results exceeded expectations, driven by a healthy showing for the Life Science and Electronics businesses, whereas Healthcare continued to ...
07/08/26
Genmab’s Q2 performance exceeded expectations. The blood cancer drug Darzalex demonstrated strong results, with other drugs also showing solid ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...